GO TO CMA Home
GO TO Inside CMA
GO TO Advocacy and Communications
GO TO Member Services
GO TO Publications
GO TO Professional Development
GO TO Clinical Resources

GO TO What's New
GO TO Contact CMA
GO TO Web Site Search
GO TO Web Site Map


CMAJ
CMAJ - June 13, 2000JAMC - le 13 juin 2000

Advertisement for Relenza

CMAJ 2000;162:1662

See response from: M.D. Levy
Print ads for Relenza (zanamivir) that have appeared in CMAJ recently state clearly that "patients should be advised of the conditional nature of the market authorization for this indication." However, the patient information booklet on influenza published by Glaxo Wellcome does not mention this. If patients should be advised of something, wouldn't the patient information pamphlet be the place to advise them? When I explain to patients my refusal to prescribe it prophylactically they are sceptical because no advisory on the conditional nature of the authorization appears in the patient brochure.

Deena Ages
Family physician
Toronto, Ont.

Comments Send a letter to the editor
Envoyez une lettre à la rédaction

© 2000 Canadian Medical Association or its licensors